vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Invesco Mortgage Capital Inc. (IVR). Click either name above to swap in a different company.
Invesco Mortgage Capital Inc. is the larger business by last-quarter revenue ($21.3M vs $15.0M, roughly 1.4× CHAMPIONS ONCOLOGY, INC.). Invesco Mortgage Capital Inc. runs the higher net margin — 242.2% vs 1.8%, a 240.5% gap on every dollar of revenue. On growth, Invesco Mortgage Capital Inc. posted the faster year-over-year revenue change (55.4% vs 11.5%). Over the past eight quarters, Invesco Mortgage Capital Inc.'s revenue compounded faster (74.2% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.
CSBR vs IVR — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $21.3M |
| Net Profit | $268.0K | $51.5M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | — |
| Net Margin | 1.8% | 242.2% |
| Revenue YoY | 11.5% | 55.4% |
| Net Profit YoY | -63.2% | 1368.7% |
| EPS (diluted) | $0.02 | $0.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $21.3M | ||
| Q3 25 | $14.0M | $17.6M | ||
| Q2 25 | $12.4M | $17.7M | ||
| Q1 25 | $17.0M | $18.8M | ||
| Q4 24 | $13.5M | $13.7M | ||
| Q3 24 | $14.1M | $7.5M | ||
| Q2 24 | $14.0M | $8.6M | ||
| Q1 24 | $12.0M | $7.0M |
| Q4 25 | $268.0K | $51.5M | ||
| Q3 25 | $-436.0K | $53.5M | ||
| Q2 25 | $-1.8M | $-23.3M | ||
| Q1 25 | $4.5M | $19.6M | ||
| Q4 24 | $728.0K | $3.5M | ||
| Q3 24 | $1.3M | $40.7M | ||
| Q2 24 | $-109.0K | $-13.5M | ||
| Q1 24 | $-2.5M | $29.1M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | — | ||
| Q3 25 | -3.8% | — | ||
| Q2 25 | -16.2% | — | ||
| Q1 25 | 26.4% | — | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | 9.5% | — | ||
| Q2 24 | -1.9% | — | ||
| Q1 24 | -21.4% | — |
| Q4 25 | 1.8% | 242.2% | ||
| Q3 25 | -3.1% | 303.6% | ||
| Q2 25 | -14.9% | -131.6% | ||
| Q1 25 | 26.4% | 104.4% | ||
| Q4 24 | 5.4% | 25.6% | ||
| Q3 24 | 9.3% | 542.2% | ||
| Q2 24 | -0.8% | -155.9% | ||
| Q1 24 | -21.1% | 415.9% |
| Q4 25 | $0.02 | $0.72 | ||
| Q3 25 | $-0.03 | $0.74 | ||
| Q2 25 | $-0.12 | $-0.40 | ||
| Q1 25 | $0.31 | $0.26 | ||
| Q4 24 | $0.05 | $-0.09 | ||
| Q3 24 | $0.09 | $0.63 | ||
| Q2 24 | $-0.01 | $-0.38 | ||
| Q1 24 | $-0.19 | $0.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $56.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $797.5M |
| Total Assets | $30.2M | $6.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $56.0M | ||
| Q3 25 | $10.3M | $58.5M | ||
| Q2 25 | $9.8M | $59.4M | ||
| Q1 25 | $3.2M | $42.9M | ||
| Q4 24 | $2.8M | $73.4M | ||
| Q3 24 | $2.9M | $48.3M | ||
| Q2 24 | $2.6M | $58.8M | ||
| Q1 24 | $4.5M | $59.9M |
| Q4 25 | $4.2M | $797.5M | ||
| Q3 25 | $3.5M | $769.6M | ||
| Q2 25 | $3.8M | $709.4M | ||
| Q1 25 | $5.5M | $759.2M | ||
| Q4 24 | $681.0K | $730.7M | ||
| Q3 24 | $-332.0K | $857.0M | ||
| Q2 24 | $-1.9M | $759.2M | ||
| Q1 24 | $-2.1M | $785.6M |
| Q4 25 | $30.2M | $6.5B | ||
| Q3 25 | $30.5M | $6.0B | ||
| Q2 25 | $32.3M | $5.4B | ||
| Q1 25 | $30.6M | $6.2B | ||
| Q4 24 | $25.2M | $5.7B | ||
| Q3 24 | $24.9M | $6.1B | ||
| Q2 24 | $26.1M | $5.1B | ||
| Q1 24 | $26.8M | $5.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $157.1M |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -13.1% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | -6.47× | 3.05× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $157.1M | ||
| Q3 25 | $600.0K | $37.3M | ||
| Q2 25 | $6.9M | $40.6M | ||
| Q1 25 | $490.0K | $19.3M | ||
| Q4 24 | $-283.0K | $183.2M | ||
| Q3 24 | $311.0K | $30.8M | ||
| Q2 24 | $-1.8M | $33.0M | ||
| Q1 24 | $-919.0K | $57.5M |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $554.0K | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | -13.1% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -8.4% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | -6.47× | 3.05× | ||
| Q3 25 | — | 0.70× | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | 0.98× | ||
| Q4 24 | -0.39× | 52.24× | ||
| Q3 24 | 0.24× | 0.76× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
IVR
Segment breakdown not available.
